Costa Group Holdings $CGC $CGC.AX is Australia’s largest grower, packer and marketer of fresh fruit and vegetables. If you like your berries, mushrooms, tomatoes, avocados and citrus, maybe you’ll like the taste of Costa Group.
Let’s take a deep dive. 👇
1. Investment thesis:
✅Stalwart.
✅Market leading position in multiple growing consumer staples lines.
✅International expansion.
✅Generating decent operating free cash flow.
✅Trading at 52 week lows.
🚩CAPEX requirements
🚩Margins & growth rates.
2. Costa’s has grown over the years by modernising fruit and veg growing – bringing new varieties, 52-week availability to supermarkets, economies of scale, and locations near to major urban centres.
3. Costa's aim to be a diversified sustainable commercial agriculture firm.
While this approach is capital intensive, this is also creates barriers to entry and potentially market power.
4. The crops Costa focuses on tend to be higher margin: tomatoes in greenhouses, vertical farmed mushrooms, year-round berries, avocados for millennial renters, etc.
5. The main segment for Costas is Australian produce supply – typically been +75% of revenue with around 10% EBITDA margins. This has been growing slowly, and can be quite volatile.
6. An example of volatility in a key market is the price of avocados have plummeted due to oversupply – finally perhaps some of those millennials may be able to afford avocado on toast and a home mortgage? bloomberg.com/news/articles/…
7. Farms and logistics provides supply chain support to third parties. While it’s ~12% of revenues, it has thin EBITDA margins of ~10% and has not been slow growing if you remove the acquisitions.
8. International has been a major growth area.
While it’s only ~25% of revenue, it has contributed 60-70% of EBITDA over the past 12 months due to it’s high margins. It is a fast growing segment across both their Africa and China berry footprints.
9. Using their patented jumbo berries and IP in efficient growing, they have been able to get footholds into the larger Africa/European and Chinese market. However, while they don’t have the duopoly supermarkets to deal with, they also don’t have strong retail channels.
10. The recent 2PH acquisition is also interesting. While it’s low-margin high-volume citrus, they are buying a range of trademarked varieties in established yet young (growing) orchards.
11. 2PH is also a massive shift from domestic to export focused production. Margins are higher, EBITDA is accretive instantly, and could become a platform for other exports. But at $190m (or 7xEBITDA), it will require decent growth.
12. Costa sells mostly into a concentrated market of Woolies $WOW Coles $COL and Metcash $MTS – so they don’t have a lot of pricing power. afr.com/companies/reta…
13. Labour shortages for fruit / veggie producers is a major risk. This is driving up costs, and literally harvests are being left to rot. They can’t pass on a lot of these costs. abc.net.au/news/rural/202…
14. Weather and disease risks are always present – the outlook for FY22 already sees an avocado glut exacerbated by poor berry volumes. It’s a fine line to get strong volumes and prices.
15. CAPEX remains very high. In 2018-20, they depreciated ~$210m and invested in ~$300m CAPEX (+$90m net growth CAPEX), contrasted with a total ~$290m of cash flow from operations.
16. Future plans are to continue growth CAPEX in the face of high maintenance CAPEX. Resultantly, there has been increasing debt (+800m/3yrs) and shareholder dilution ($175m or 27% / 3yrs, 100% / 7yrs).
17. Despite the share price catering 40% past six months, it’s still trading at PE=22. While it’s not so bad on EV/EBITDA=10, the massive CAPEX requirements makes this immaterial. Even factoring in accretive 2PH earnings, the PE=20.5.
18. Where’s the growth going to come from?
Personally, I don’t see any real catalyst beyond the organic growth of international sales – which I also think is the riskiest as it is an area that is farthest from their circle of competence.
19. h/t @berthon_jones who also has been highlighting some of the terrible momentum and valuations
Angel Seafood $AS1 $AS1.AX is the largest oyster producer in Coffin Bay, making news for all the wrong reasons. A real microcap seeking to build scale, is now the time to swim against the tide? 🦪
Let’s take a deep dive. 👇
1. Investment thesis: Fast Grower.
✅Strong market for oysters
✅Revenue ramping up
✅CAPEX pulling back
✅Biomass in place for scaling
✅Skin in the game
🚨Food poisoning / sales suspension
2. Recently I looked at East 33 $E33 as an oyster play – sorry folks, it was a ruse!
That was my competitor research on Angel, which has taken a lot longer to get my head around due to the lack of information available.
East 33 $E33 $E33.AX is a premium Sydney Rock Oyster company that recently IPO’d. Substantive performance rights for management with a colourful history will likely drive a debt-fueled acquisition binge and short term shareholder returns.
Let’s take a deep dive. 👇
1. Investment thesis: Special situation.
✅Fast top-line growth driven by acquisitions.
✅Strong market conditions.
🚩Performance incentives for EBIT and share price growth.
🚩Debt financed.
🚩History of poor management.
2. East 33 farms native Sydney Rock Oysters – a premium product.
Vertically integrated, they have an export approved facility, export certificate, 195ha of farming licenses, and a nursery.
Wake up to find out Europe is in a gas crisis, Barnaby Joyce is worried about burping cows, and now you find your portfolio is underweight #seaweed ? Me too.
Let's take a look at 'Australian Seaweed As A Megatrend' 👇
1. Investment Thesis: Early stage investing in seaweed as a nascent industry with significant growth potential due to multiple mega trends (climate change, organic fertilizers, food security, and biopharma); moving from research into commercialisation.
2. What is seaweed?
Seaweed biomass can be used for an array of possible uses including food, animal feed, high-value pharmaceutical/ industrial compounds, biofuels, and fertilisers. It's grown in water, and has environmental benefits.
Rubicon Water Limited $RWL $RWL.AX is an irrigation efficiency hardware and software company. They've built out from Australia into US, Europe and recently China and India - big markets. After successfully IPO'ing this month, they're up 75%.
Genex $GNX $GNX.AX is a renewable energy developer with a focus on firming through pumped hydro and batteries. After 6yrs in the sin bin for epic delays, what's changed?
@ElephantCapita2 will also share his technical analysis to answer 'why now?'
Let’s take a deep dive.👇
1. Investment thesis: Turnaround / Asset play.
A high CAPEX company, in a growing sector, potential takeover target, progressed through multiple de-risking events, but due to failures since IPO in 2015 its priced markedly below fair value.
Potential to become a stalwart?🤷
2. Growing demand for renewables.
There’s a long tailwind of renewable energy growth, both as total consumption increases and renewables replace fossils. Wind, solar and other (inc. bioenergy) are growing, and Genex is positioning itself in that super fast growing space.
Avita Medical Inc. $AVH $AVH.AX is best known for its product ReCell $RCEL – spray on skin for burns victims. After a long history of innovation, commercial success has evaded this once-darling. Is this time different?
Let’s take a deep dive on 3 key metrics to watch.👇
1. Investment thesis: Fast grower / turnaround.
Innovative product with clear use case, competition falling way, optionality on new applications, top-line growth as adoption improves. Questionable management.
2. History in a nutshell. Founded as ‘Clinical Cell Culture’ in 1993 by Prof. Fiona wood who developed the tech with Marie Stone. First big test for ReCell was after the 2002 Bali Bombings treating the burn victims. renamed Avita in 2008.